[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361388-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361388-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-characterization-of-met-exon-14-skipping-mutations-in-non-small-cell-lung-cancer","Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer","","MET exon 14 skipping mutation (METΔex14) is a key driver in non-small cell lung cancer (NSCLC) and may arise as acquired resistance to MET, EGFR, or ALK inhibitors. A cohort of 585 METΔex14+ NSCLC patients was analyzed using targeted next-generation sequencing of tissue and/or plasma. METΔex14 prevalence was 1.02% and higher in sarcomatoid histology, with frequent splice-site detection. Baseline concurrent alterations, links to crizotinib outcomes, and mechanisms of acquired resistance—including FGFR3::TACC3 as a potential savolitinib resistance factor—were identified.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-characterization-of-met-exon-14-skipping-mutations-in-non-small-cell-lung-cancer/361388/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-characterization-of-met-exon-14-skipping-mutations-in-non-small-cell-lung-cancer/361388.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is METΔex14 and why is it important in NSCLC?","Question",{"text":63,"@type":64},"MET exon 14 skipping mutation (METΔex14) is a key oncogenic driver event in NSCLC. It can also emerge as an acquired drug-resistance mechanism to MET, EGFR, or ALK inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed to characterize METΔex14?",{"text":68,"@type":64},"The study included 585 METΔex14+ NSCLC patients and analyzed genomic data from tissue and/or plasma. Targeted next-generation sequencing was performed using a pan-cancer gene panel (GeneseeqPrime™).",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were associated with resistance to MET inhibitors and treatment response?",{"text":72,"@type":64},"Acquired resistance mechanisms were primarily attributed to on-target MET D1228X/Y1230X mutations or off-target alterations in RTK/RAS/MAPK and PI3K/AKT/mTOR pathways. Increased chromosomal instability and intra-tumoral heterogeneity correlated with poorer response to crizotinib, and FGFR3::TACC3 was identified as a potential savolitinib resistance mechanism.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361388,1790320003,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Lin etal. Respiratory Research (2026) 27:342 Respiratory Research  \n[https://doi.org/10.1186/s12931-026-03626-1](https://doi.org/10.1186/s12931-026-03626-1)  \nRESEARCH Open Access  \nComprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer  \nJie Lin1*†, Guojie Xia2†, Yijuan Wu1, Lingfeng Chen1, Yaru Zhang3, Ya Ma3, Jiani C. Yin3, Zhenyu Zhang4* and Xiaojie Pan5*  \nAbstract  \nBackground MET exon 14 skipping mutation (METΔex14) is a key driver event in non-small cell lung cancer (NSCLC) and can emerge as an acquired drug resistance mechanism to MET, EGFR or ALK inhibitors. The clinical and genomic features of METΔex14 in NSCLC require further characterization.  \nMethods Our study included a total of 585 patients with METΔex14 + NSCLC, comprising 556 baseline samples, 53 samples from patients exhibiting resistance to MET inhibitors, and 16 samples from patients resistant to EGFR/ALK inhibitors. Genomic data from targeted next-generation sequencing (NGS) of tissue and/or plasma samples using GeneseeqPrime™ (a 425 pan-cancer gene panel) were analyzed.  \nResults Overall, METΔex14 exhibited a prevalence of 1. 02%(n = 585) in the screened NSCLC population, with a higher incidence in patients with a sarcomatoid histology. METΔex14 was predominantly detected at the splice donor site, though the non-coding region adjacent to the splice acceptor site contributed considerably to the complexity of METΔex14 . Common concurrent alterations identified at baseline included those in TP53 (40 . 8%), CDK4 (16%) and EGFR (12 .4%) . Concurrent MET amplification and cell cycle pathway mutations were both associated with worse outcomes in patients treated with crizotinib, with significant co-occurrences observed also among these concurrent genomic variations. In addition, increased chromosomal instability and intra-tumoral heterogeneity correlated with a poorer response to crizotinib. Mechanisms of acquired resistance to MET inhibitors were primarily attributed toon-target MET D1228X/Y1230X mutations or off-target alterations within genes in the RTK/RAS/MAPK and PI3K/AKT/ mTOR pathways. Intriguingly, our exploratory analysis also identified the FGFR3::TACC3 fusion as a potential resistance mechanism to savolitinib. Moreover, METΔex14 was identified in 16 patients following progression on EGFR and ALK inhibitors, highlighting the need for developing tailored therapeutic strategies to overcome resistance.  \n†Jie Lin and Guojie Xia contributed equally to this work.  \n*Correspondence:  \nJie Lin  \n[sllinjie@163.com](sllinjie@163.com)[ ](sllinjie@163.com)Zhenyu Zhang [zhangzhenyu01@163.com](zhangzhenyu01@163.com)[ ](zhangzhenyu01@163.com)Xiaojie Pan [pxj1028@hotmail.com](pxj1028@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLin et al. Respiratory Research ","cbCailuZL3jQgdJM","https://ap.wps.com/l/cbCailuZL3jQgdJM","pdf",4914963,13,"English","# Abstract\n# Background\n## MET gene and METΔex14 biology\n## Prevalence and rationale for MET-targeted TKIs\n# Methods\n## Patient cohort and sample breakdown\n## Targeted NGS approach","[{\"question\":\"What is METΔex14 and why is it important in NSCLC?\",\"answer\":\"MET exon 14 skipping mutation (METΔex14) is a key oncogenic driver event in NSCLC. It can also emerge as an acquired drug-resistance mechanism to MET, EGFR, or ALK inhibitors.\"},{\"question\":\"How was the study designed to characterize METΔex14?\",\"answer\":\"The study included 585 METΔex14+ NSCLC patients and analyzed genomic data from tissue and/or plasma. Targeted next-generation sequencing was performed using a pan-cancer gene panel (GeneseeqPrime™).\"},{\"question\":\"What factors were associated with resistance to MET inhibitors and treatment response?\",\"answer\":\"Acquired resistance mechanisms were primarily attributed to on-target MET D1228X/Y1230X mutations or off-target alterations in RTK/RAS/MAPK and PI3K/AKT/mTOR pathways. Increased chromosomal instability and intra-tumoral heterogeneity correlated with poorer response to crizotinib, and FGFR3::TACC3 was identified as a potential savolitinib resistance mechanism.\"}]","Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer | PDF",1790144156,33,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d948c33081d14e7ac308ddf481164e28.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd88e0f207749fdd867b0dc35ed6684b.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4def474b95139c4dea555e0ca0c3fcea.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14231f9c6eea9250bf80262c48e1b68f.webp",980,1306]